The strategic partnership between Myriad and Illumina consists of a time-limited exclusive agreement for Illumina to provide a kit-based version of the myChoice CDx test for international markets.
Read More
The FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests.
Read More
The self-administered, noninvasive saliva kits are FDA authorized for use by both individuals with and without symptoms of covid-19.
Read More
Through the agreement, Fulgent will provide covid-19 testing for thousands of students and employees at many K-12 schools in New York City on a daily basis.
Read More
The new EuroRealTime test allows fast detection and differentiation of genetic material from SARS-CoV-2, influenza virus type A, and influenza virus type B using throat swab samples of patients with acute symptoms.
Read More